ChromaDex Begins Human Trial on Caffeine Ingredient

Will human results support previous work on Purenergy in animals?

Just weeks after announcing its commercial launch of Purenergy, ChromaDex Corp. (Irvine, CA) says it is beginning a first human study on the combination formula of caffeine and pterostilbene. The purpose of the human study is to demonstrate the ingredient’s safety and bioavailability, and hopefully confirm results of animal research showing that the product has a longer half life than caffeine alone.

ChromaDex is introducing its novel crystalline ingredient at a time when energy ingredients, especially caffeine, are under increasing scrutiny.